C1 Esterase Inhibitor, Recomb
Brand name: Ruconest
Rank #498 of 500 drugs by total cost
$13.8M
Total Cost
155
Total Claims
$13.8M
Total Cost
8
Prescribers
$89K
Cost per Claim
0
Beneficiaries
155
30-Day Fills
$1.7M
Avg Cost/Provider
19
Avg Claims/Provider
About C1 Esterase Inhibitor, Recomb
C1 Esterase Inhibitor, Recomb (sold as Ruconest) was prescribed 155 times by 8 Medicare Part D providers in 2023, costing the program $13.8M. At $89K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 495 | Glecaprevir/Pibrentasvir (Mavyret) | $14.1M | 1,011 |
| 496 | Pacritinib Citrate (Vonjo) | $13.9M | 626 |
| 497 | Olmesartan/Hydrochlorothiazide (Olmesartan-Hydrochlorothiazide) | $13.9M | 246,637 |
| 498 | C1 Esterase Inhibitor, Recomb (Ruconest) | $13.8M | 155 |
| 499 | Sildenafil Citrate (Sildenafil Citrate) | $13.8M | 248,961 |
| 500 | Lovastatin (Lovastatin) | $13.6M | 981,262 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology